Clinical Trial Update: 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating samarium-153-EDTMP with or without PSA/TRICOM vaccine in men with androgen-insensitive (castration-resistant) prostate cancer; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• PSA/TRICOM vaccine (PSA-TRICOM)
• Quadramet (samarium-153 lexidronam pentasodium)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-07-01